ONCY — Oncolytics Biotech Share News
0.000.00%
Brief: Oncolytics Biotech Inc reports qtrly share of $0.02
Brief: Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysin
Brief: Oncolytics Biotech announces first patient treated in Muk Eleven study
Brief: Oncolytics Biotech Inc's qtrly loss per share $0.03
Brief: Oncolytics Biotech granted end-of-phase 2 meeting with FDA
Brief: Oncolytics Biotech Inc announces FDA fast track designation for Reolysin
Brief: Oncolytics Biotech Q1 loss per share $0.03
Brief: Oncolytics Biotech announces registration pathway and clinical development plan
Brief: Oncolytics Biotech says Reolysin doubles survival in breast cancer patients
Brief: Oncolytics Biotech enters collaboration with Myeloma UK and Celgene
Brief: Oncolytics Biotech says Canadian Cancer Trials Group to present metastatic breast cancer study data
Brief: Oncolytics Biotech names Matt Coffey CEO
Brief: Oncolytics Biotech announces change to Board of Directors
Brief: Oncolytics provides initial data on combination therapy with Reolysin in multiple myeloma patients
Brief: Oncolytics Biotech appoints of new chief medical officer
Brief: Oncolytics Biotech - Qtrly loss per share $0.03
Brief: Oncolytics Biotech Qtrly basic and diluted loss per common share $0.03
Brief: Oncolytics Biotech Inc announces appointment of Matt Coffey as interim President and Chief Executive Officer
Brief: Oncolytics reports additional data from phase II study of Reolysin